Ocular Therapeut - OCUL STOCK NEWS

Ocular Therapeutix (NASDAQ: OCUL) has announced it will host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss its fourth quarter and full year 2024 financial results and recent business developments. The company, which focuses on redefining the retina experience, will provide access to the event through both U.S. (1-877-407-9039) and International (1-201-689-8470) dial-in numbers. The webcast will be available live and archived on the company's Investor Relations page for at least 30 days following the presentation.

Ocular Therapeutix (NASDAQ: OCUL) has announced multiple presentations scheduled for the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The presentations will focus on their key product OTX-TKI, featuring three distinct sessions:

1. Dr. Carl J. Danzig will present on OTX-TKI's progression from Phase 1 to Phase 3, discussing the SOL-1 and SOL-R trials for neovascular AMD at 2:30 PM ET.

2. Dr. Mark R. Barakat will share Phase 1 results of the intravitreal axitinib implant (OTX-TKI) for treating non-proliferative diabetic retinopathy at 5:20 PM ET.

3. Dr. Justis P. Ehlers will present volumetric macular fluid analysis findings from the HELIOS Clinical Trial at 5:25 PM ET, examining the impact of a single axitinib intravitreal implant in diabetic retinopathy treatment.

Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards granted to a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The awards, effective January 13, 2025, include:

1. A non-statutory stock option to purchase 95,600 shares at market price, vesting over four years with 25% vesting on January 13, 2026, and the remainder monthly over three years.

2. A restricted stock unit award for 31,375 shares, vesting in equal annual installments over three years, starting January 13, 2026.

Both awards are contingent on continued employment with Ocular through the vesting dates.

Ocular Therapeutix (NASDAQ: OCUL) reported significant progress in its AXPAXLI™ clinical trials for wet age-related macular degeneration (wet AMD) and plans for non-proliferative diabetic retinopathy (NPDR). The company has enrolled 311 subjects in SOL-R, its second registrational trial for wet AMD, while completing randomization for SOL-1, its first registrational trial, with topline data expected in Q4 2025.

The company's wet AMD program consists of two complementary studies: SOL-1, a superiority trial comparing single AXPAXLI injection to aflibercept, and SOL-R, a non-inferiority trial evaluating repeat AXPAXLI injections. Both trials are designed to support a potential New Drug Application.

Following positive results from the Phase 1 HELIOS trial for NPDR, where no patients developed vision-threatening complications after 48 weeks with a single AXPAXLI injection, Ocular plans to seek FDA feedback on clinical trial design in H1 2025.

Ocular Therapeutix (NASDAQ: OCUL) announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 5:15 PM PT in San Francisco. Pravin U. Dugel, MD, the company's Executive Chairman, President and CEO, will provide updates on several key areas including:

- The enrollment status of SOL-R, their second registrational trial of AXPAXLI™ for treating wet age-related macular degeneration (wet AMD)
- Future opportunities for AXPAXLI
- A general corporate overview and strategic outlook for 2025

The presentation will be accessible through the Events and Presentations section of the company's Investor Relations webpage.

Ocular Therapeutix (NASDAQ:OCUL) has announced inducement awards for a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The awards, effective December 9, 2024, include:

- Non-statutory stock options to purchase 215,000 shares at market price, vesting over 4 years with 25% after first year and remaining monthly over 3 years

- Restricted stock unit awards for 70,000 shares, vesting in equal annual installments over 3 years starting December 9, 2024

Both awards are contingent on continued employment with the company.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place from January 13-16, 2025, in San Francisco, CA. Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will deliver the company's presentation on Monday, January 13, 2025, at 5:15 PM PT.

The presentation will be accessible through a live webcast on the Events and Presentations section of the company's Investor Relations webpage. Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing innovative therapies for retinal diseases and other eye conditions, with the mission of improving real-world vision.

Ocular Therapeutix (NASDAQ: OCUL) has announced significant progress in its Phase 3 clinical trials for AXPAXLI™ in wet AMD treatment. The company has successfully randomized over 300 patients in its first registrational trial, SOL-1, which is expected to close randomization this week. Topline data from SOL-1 is anticipated in Q4 2025. The company's second registrational trial, SOL-R, is now accepting direct patient enrollment at active clinical sites, accelerating recruitment pace. Both trials are designed to evaluate AXPAXLI's potential as a durable treatment option that could be dosed every six to nine months for wet AMD patients.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in key December investor and scientific conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference with a fireside chat on December 3rd, 2024, featuring CEO Pravin U. Dugel. Additionally, the company will have a significant presence at FLORetina ICOOR 2024 in Florence, Italy, with multiple presentations scheduled between December 5-7, 2024.

The presentations will focus on their OTX-TKI treatment, including 48-week results from the HELIOS Phase I Trial for non-proliferative diabetic retinopathy, and discussions on TKIs in retinal disease management. Multiple sessions will feature presentations by leading medical experts including Dr. Dilsher S. Dhoot and Dr. Diana V. Do.